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Abstract
After the introduction of statins in the market as effective lipid lowering agents, they were shown
to have effects other than lipid lowering. These actions were collectively referred to as 'pleiotropic
actions of statins.' Pleiotropism of statins formed the basis for evaluating statins for several
indications other than lipid lowering. Evidence both in favour and against is available for several of
these indications. The current review attempts to critically summarise the available data for each
of these indications.
Recently while browsing through the internet, we came
across a webpage [1] that reads as follows: "Statin drugs
should probably be in the water, like fluoride. These cho-
lesterol fighting wonders have been proven to prevent
heart attacks..... with only rare side effects............... The
hitch is that statins cost more than fluoride. A lot more.
The drug industry's statin sales surpassed US $15 billion
last year. The cholesterol fighting power of products like
Pfizer's Lipitor and Merck's Zocor have won them the title
'Superstatins' and made them supersellers. Lipitor
brought in US $9.2 billion in 2003 sales for Pfizer, mak-
ing it the biggest prescription drug in the world."
In 2001, we reviewed the statin literature for Medscape
and were able to enlist about seven indications[2], the
major one being dyslipidemia with associated coronary
disease (CAD). The 1993 National Cholesterol Education
Programme (NCEP) guidelines [3] were cautiously opti-
mistic about the future of statins but subsequent publica-
tion of 3 landmark trials [4-6], greatly tilted the balance in
their favour and since then they haven't looked back: a
large number of trials and guidelines added new intensity
to cholesterol lowering with the low density lipoprotein
cholesterol (LDL-C) targets going for a free fall (<70 mg/
dl in some situations) [7-12]. Although this approach of
more intense lipid lowering has met with considerable
criticism, this is not the topic of this review. We intend to
discuss the other novel, upcoming uses of statins.
In contrast to the post-hoc analysis of the Scandinavian
Simvastatin Survival Study (4S) [4] in which the benefit
provided was related to the magnitude of change in the
LDL-C levels, some other studies have shown benefits that
could not be accounted for by reduction in LDL-C alone
[13-16]. A large number of studies showing pleiotropism
of statins followed and diverse mechanisms were then
proposed to explain this pleiotropism including anti-
inflammatory, immunomodulating, and effects on apop-
tosis [17-22], making them potentially suitable candi-
dates for the treatment of a wide variety of pathological
conditions in many of which they are already being
investigated.
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This article attempts to summarize the available evidence
for the proposed (other than lipid lowering) indications
of statins.
Arrhythmias
Several actions of lipid lowering therapy like reduction in
myocardial ischemia, improvement of autonomic func-
tion, changes in protein channel function and inhibition
of cardiac remodelling make them prospective agents for
the treatment of arrhythmias[22,23]. Chronically admin-
istered pravastatin was shown to reduce the incidence of
ischemia-induced ventricular tachyarrhythmias in experi-
mental models [24,25]. Early use of pravastatin in
patients with acute myocardial infarction (MI) reduced
the incidence of in-hospital ventricular arrhythmias irre-
spective of the lipid levels [26]. The Anti-arrhythmia Ver-
sus Implantable Defibrillators (AVID) Study showed that
lipid lowering therapy decreased the recurrence rate of
ventricular arrhythmias in patients implanted cardio-
verter-defibrillator [27].
Statins have also been shown to have a role in the treat-
ment of atrial arrhythmias. Inflammatory changes have
been shown in atrial biopsy specimens of patients with
lone atrial fibrillation (AF) [28]. Furthermore, serum lev-
els of C-reactive protein (CRP), a sensitive marker of sys-
temic inflammation, were increased in patients with AF.
Not only that, CRP levels were higher in patients with per-
sistent rather than paroxysmal AF, and persistent AF is less
likely to spontaneously revert to sinus rhythm [29,30].
These studies suggested that inflammation may induce,
provoke and promote the persistence of AF. Statins may
be potent anti-inflammatory agents [31] and have also
been shown to reduce CRP levels [32].
Not surprisingly, statins were subsequently shown to pre-
vent AF recurrence in patients with lone AF after successful
cardioversion [33] and in patients with CAD[34]. Both
these studies were retrospective. However, it is well
known that results obtained in retropsective studies may
not be replicated in clinical trials [35]. Accordingly, in an
open, controlled multicenter study, pravastatin did not
reduce the recurrence rate of AF after electroversion[36].
Moreover, there has been an isolated case report of AF due
to simvastatin[37], which further limits their role in the
management of arrhythmias.
The evidence available for the beneficial role of statins is
largely from observational and experimental studies
which is clearly insufficient to recommend them as pri-
mary or even adjunctive antiarrhythmic agents. Moreover,
their role in prevention as well as treatment of arrhyth-
mias remains to be clearly defined.
Heart failure
Initial experimental evidence indicated towards both
potential harm and benefit of statins in heart failure. Stat-
ins modulate a variety of inflammatory and immune
responses [38-40]. In animal models of heart failure, stat-
ins moderate abnormal collagen and β -myosin expres-
sion, attenuate increased matrix metalloproteinase
activity, improve ventricular remodelling and systolic
function, normalize sympathetic responses and improve
survival [41-43] Given the relation of systemic inflamma-
tion to morbidity and mortality in heart failure patients, it
was hypothesised that statins may benefit patients with
heart failure separately from or in addition to effects on
cholesterol and coronary disease[44].
In a report of 551 patients with systolic heart failure, statin
use was associated with improved survival in patients with
ischemic and non-ischemic heart failure[45]. After risk
adjustment for age, gender, CAD, cholesterol, diabetes,
medication, hemoglobin, creatinine and NYHA func-
tional class, statin therapy remained an independent pre-
dictor of improved survival. Furthermore, in a
randomised trial in 63 patients with heart failure, statin
use improved NYHA class and ejection fraction when
compared with placebo [46]. Also, statin therapy reduced
new onset heart failure in the 4S Study [47], but this may
have been related to effects on recurrent myocardial inf-
arction. Using data from the Prospective Randomised
Amlodipine Survival Evaluation (PRAISE) trial, associa-
tion of statin therapy with total mortality among 1,153
patients with severe heart failure was evaluated [48]. Sta-
tin therapy was associated with a 62% lower risk of death.
However, only 12% patients were receiving statin therapy.
Moreover, the study results cannot be generalised as these
patients participated in a clinical trial at a time when β
blockers and spironolactone were not commonly used in
severe heart failure.
There also is some evidence to the contrary; lower serum
cholesterol predicts worse outcomes in heart failure [49],
raising concerns regarding use of lipid lowering agents.
Statins also reduce ubiquinone (enzyme Q-10) [50],
which may adversely affect mitochondrial and cardiac
muscle function.
Therefore, in lieu of conflicting experimental and clinical
data, the routine use of statins in congestive heart failure
will be premature.
Cardiomyopathy (CMP)
In initial experimental studies, simvastatin was shown to
induce regression of cardiac hypertrophy and fibrosis and
improve cardiac function in a transgenic rabbit model of
human hypertrophic CMP [51]. Based on the knowledge
that statins improve endothelial function [39] andJournal of Negative Results in BioMedicine 2005, 4:3 http://www.jnrbm.com/content/4/1/3
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suppress systemic inflammation [31], it was hypothesized
that statins may improve cardiac function in patients with
nonischemic dilated CMP [46]. Fourteen weeks of treat-
ment with simvastatin was shown to improve left ven-
tricular ejection fraction, reduce plasma concentration of
tumour necrosis factor-alpha, and brain natriuretic factor
in patients with idiopathic dilated CMP[52]. The effect on
patient outcomes was however not evaluated.
Again as in case of heart failure, although some evidence
is available for the beneficial effect of statins in CMP, evi-
dence to the contrary is also available. Lovastatin has been
shown to significantly increase mortality in hamsters with
cardiomyopathic heart due to reduction in ubiquinone
supply[53]. Statins have been shown to decrease coen-
zyme Q levels in humans [54] and this coenzyme is indis-
pensable for cardiac functions [55]. In wake of such
conflicting evidence, their use in ishemic/nonishemic
CMP cannot be advocated.
Diabetic dyslipidemia
In addition to microvascular complications, patients with
type 2 diabetes are at an increased risk of developing CAD
[56] Over a 7-year period, in patients with no history of
CAD, the incidence of first MI was over five times greater
for patients with diabetes compared with non-diabetic
controls [57]. Diabetes is now considered to be a cardio-
vascular disease and all diabetics, irrespective of history of
CAD, are considered within the category of secondary
CAD prevention. Diabetic dyslipidemia may exist in the
absence of raised total serum cholesterol due to an
increased proportion of the more atherogenic LDL parti-
cles. Moreover, dyslipidemia often exists with a number of
other atherogenic co-factors in patients with diabetes (e.g.
abdominal obesity and hyperinsulinemia) as a part of
metabolic syndrome [58]. The updated Adult Treatment
Panel (ATP)-III guidelines have advocated the use of stat-
ins for diabetes with or without CAD [12]. LDL lowering
treatment when LDL-C is >100 mg/dL in diabetices with-
out CAD and >70 mg/dL in diabetics with CAD has been
recommended.
Since the appearance of the first report on the efficacy of
statins in lowering lipid concentrations in patients with
type 2 diabetes [59], clinical trial evidence has accumu-
lated in their support as the primary lipid-lowering drugs
for these patients. Subgroup analyses [60] of diabetic
patients in the Antihypertensive and Lipid Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT-LLT) [9], the
MRC/BHF Heart Protection Study (HPS) [15], and the
Anglo-Scandinavian Outcomes Trial-Lipid Lowering Arm
(ASCOT-LLA) [10] showed variable results of lipid lower-
ing therapy on cardiovascular outcomes in diabetic
patients. In ALLHAT-LLT [9] pravastatin did not reduce
the incidence of non-fatal MI and CAD deaths in patients
with diabetes. In the HPS trial [15] simvastatin signifi-
cantly reduced the risk of CAD and total cardiovascular
events in patients with diabetes, whether they already had
CAD or not. In the ASCOT-LLA trial [10] atorvastatin did
not reduce the risk of non-fatal MI and CAD death in
patients with diabetes and hypertension who had no pre-
existing CAD. Collaborative Atorvastatin Diabetes Study
(CARDS) was carried out to evaluate the efficacy and
safety of low-dose atorvastatin treatment in primary pre-
vention of CAD in patients with type 2 diabetes at high-
risk of CAD [61]. CARDS Investigators conclude that stat-
ins should be used in all patients with type 2 diabetes
unless the patient has sufficiently low risk of coronary
heart disease.
However, generalization of CARDS results is debatable.
For example, the risk of statin therapy might be increased
in people older than 75 years of age in patients with
chronic renal insufficiency or organ transplantation and
in patients with very high triglyceride concentrations who
are on fibrates [60]. Moreover, the number needed to treat
will be very high in patients in whom the baseline risk is
low like those with type 2 diabetes who are younger than
40 years; in premenopausal women; and in those without
any CAD risk factors [60].
Development of diabetes
Lipid lowering therapy with bezafibrate had earlier shown
to improve plasma glucose levels and insulin response to
75 g oral glucose loading associated with hyperinsulin-
ema [62]. An analysis of patients enrolled in the
WOSCOPS study had shown a 30% reduction in the haz-
ard of becoming diabetic [63]. The analysis was done post
hoc and the levels of statistical significance was modest (p
= 0.04). Additionally, by reducing the risk of CAD, the
need for β -blocker use (and perhaps thiazides) was
reduced. There is some evidence that β -blockers [64,65]
and thiazides [66] may be associated with an increase in
the incidence of diabetes.
Although no effect of pravastatin on glucose levels was
shown in another study, [67] the authors proposed that
pravastatin might reduce the incidence of diabetes by a
reduction in triglyceride (TG) levels. However, even this is
unlikely because the effect of pravastatin on TG levels is
only modest [68]. A recent case control study from the UK
based General Practice Research Database failed to show
reduced incidence of development of diabetes [69].
Diabetic maculopathy
There has been interest in link between serum lipids and
retinal exudates for 40 years [70]. A number of cross-sec-
tional studies suggest that serum lipids may have a causa-
tive role in the formation of macular exudates [71-74]. A
cross-sectional study of Age-related Macular DegenerationJournal of Negative Results in BioMedicine 2005, 4:3 http://www.jnrbm.com/content/4/1/3
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(AMD) suggests that statin therapy does have a protective
role against the development of macular degeneration
[75].
Few studies have evaluated statins in diabetic retinopathy
[76,77]. In one of these, an improvement in hard exudates
was noted in all patients on statins [76]. In another study,
simvastatin was shown to improve fluoroscein angio-
graphic picture and led to maintenance of visual acuity in
all patients [78].
These data, though important, do not permit us to draw a
final conclusion as these studies were inadequately
powered.
Claudication
Claudication occurs when blood flow to the extremity
fails to meet the metabolic demands of the skeletal muscle
during exercise. It was hypothesised that statins, by
improving endothelium dependent vasodilation at the
arteriolar and capillary level [79], by their proangiogenic
response independent of cholesterol reduction [80], and
by inhibition of MMP-9 secretion by peripheral mono-
cytes [81], could be beneficial in reducing claudication in
patients with peripheral arterial occlusive disease
(PAOD). Studies with lipid modifying therapies have
demonstrated desirable effects in patients with PAOD
[82,83]. A post-hoc analysis of the 4S data showed that
new or worsening claudication was reduced in the group
of patients receiving statins [84]. High-dose, short-term
therapy with simvastatin has been shown to improve
walking performance, ankle-brachial pressure indices,
and symptoms of claudication in hypercholesterolemic
patients with PAOD [85]. One-year treatment with atorv-
astatin improved pain free walking time and participation
in physical activity in patients with intermittent claudica-
tion [86]. However, maximal walking time did not change
significantly. Similar benefit was shown with simvastatin
on treadmill exercise time until the onset of intermittent
claudication [87].
Despite the evidence from these studies suggesting bene-
fit, well-designed long-term studies assessing primary and
secondary prevention of PAOD with defined endpoints
such as amputation or number of vascular events are
required.
Multiple sclerosis (MS)
In an experimental model of encephalomyelitis, lovasta-
tin treatment was shown to block disease progression and
induction of inflammatory cytokines [88]. Lovastatin
treatment also attenuated the transmigration of mononu-
clear cells by downregulating the expression of leukocyte
function antigen-1  (LFA-1), a ligand for intercellular
adhesion molecule (ICAM), in endothelial-leukocyte
interaction [88] and mononuclear cell infiltration into the
CNS has been implicated in MS [89]. Atorvastatin was
shown to promote Th2 bias and reverse paralysis in a
CD4(+)Th1-mediated experimental model of MS [90].
Therefore, statins were recognised as potential agents for
future pharmacotherapy of MS [91]. In the first clinical
trial of statins in MS, 80 mg oral simvastatin for 6 months
significantly reduced the number and volume of gadolin-
ium enhancing lesions [92]. However, immunological
expression of surface markers on leukocyte cells or inflam-
matory cytokine profile showed no changes. Moreover, it
was an uncontrolled, open label, small study with a base-
line versus treatment comparison. Therefore, its results
must be interpreted with caution. For instance, it is possi-
ble that reduction in the disease severity as measured with
MRI could be due to regression to the mean. Moreover,
since patients were included on the basis of the presence
of gadolinium enhancement, this might have led to selec-
tion of patients with active disease who may subsequently
have shown spontaneous reduction in disease activity
anyhow. Additional factors like steroid use and unblinded
assessment of MRI scans may have influenced the results.
The exploratory immunological data in this study were
also not found to be supportive.
Due to the paucity of evidence from adequately powered
good quality clinical trials demonstrating the benefits of
statins, any conclusive statement would be rather prema-
ture. Several trials are currently underway to address this
question and we are also conducting a Double-blind, Ran-
domised Evaluation of Atorvastatin in Multiple Sclerosis
(DREAMS) trial in our institution.
Stroke
Although cholesterol lowering is well known to decrease
the risk of CAD, its association with decreased risk of
stroke was demonstrated later [93]. Meta-analyses done
recently have shown statin use to be associated with
reduced risk of stroke by 12 to 24% [94,95].
Analysis of data from nine cohort studies showed a 15%
decrease in thromboembolic stroke but a 19% increase in
hemorrhagic stroke for a 1.0 mmol/l decrease in LDL con-
centration. The risk in those without a known cardiovas-
cular risk factor was shown to be the same (6%) in clinical
trials as that seen in cohort studies [91]. Though the over-
all risk of non-fatal strokes was reduced, the risk of fatal
strokes was not [96]. Also, these results were obtained
from studies which had stroke as their secondary end-
point. Moreover, in most of the included studies, inci-
dence of stroke was very low, especially for primary
prevention, reducing the power of comparison.Journal of Negative Results in BioMedicine 2005, 4:3 http://www.jnrbm.com/content/4/1/3
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Alzheimer's disease (AD)
Addition of lovastatin to human HEK cells transfected
with the amyloid precursor protein (APP) was shown to
reduce intracellular cholesterol/protein ratios by 50%,
and to inhibit cleavage of APP by beta-secretase [97].
Non-demented individuals with heart disease have
increased prevalence of AD-like beta-amyloid deposits in
the neuropil and within neurons [98]. In a cohort of
patients taking lovastatin and pravastatin (but not simvas-
tatin), a lower prevalence of diagnosed probable AD was
noted [99]. A case control study has also shown a lower
risk of dementia among users of statins [100].
However, in a review done by the Cochrane Group, it was
pointed out that no evidence in the form of controlled
clinical trials was available to recommend the use of stat-
ins in AD [101]. In a subsequent randomised, placebo
controlled, double-blind trial, 26-week treatment with 80
mg simvastatin did not show any significant alteration in
the cerebrospinal fluid levels of A-beta 40 and A-beta 42
[102]. Though the body of evidence for the beneficial
effect of statins for AD is growing, due to the paucity of
randomised controlled trials, no conclusions can yet be
drawn [103].
Moreover, excessive lipid lowering may be detrimental as
too little cholesterol in neural membranes has been
shown to increase the vulnerability of neural membranes
to dysfunction [104]. Low serum cholesterol concentra-
tions have been shown to be associated with cognitive
decline in prospective studies of aging American twins
[105] and elderly Finns [106].
Depression
Two observational studies showed that long-term statin
use is associated with a reduced risk of depression in
patients with CAD [107,108]. After an average follow up
of 4 years, comparison of psychometric scores between
users and nonusers of statins showed that statin use was
associated with lower risk of abnormal scores for depres-
sion, anxiety and hostility [107]. Authors have attributed
the findings to a possible direct effect of statins on psycho-
logical well being. Similar reduced risk of depression was
noted with statins in patients with hyperlipidemia [108].
A more plausible possibility of reduced risk of depression
due to an improvement in the overall quality of life was
suggested in this study.
On the other hand, lowering of serum cholesterol may be
associated with an increased incidence of depression and
suicides [109-113]. To sort of neutralize the evidence,
some randomised, placebo controlled trials of statins
have shown that depression was neither more nor less
common among those taking active treatment [114-116].
Rheumatoid arthritis (RA)
Statins were shown to inhibit LFA-1, which is known to
play an important role in the pathophysiology of inflam-
matory and autoimmune diseases [117]. Statins also led
to significant suppression of collagen-specific Th 1
humoral and cellular immune responses, reduction of
anti-CD3/anti-CD28 proliferation and IFN-gamma
release from mononuclear cells derived from peripheral
blood and synovial fluid [118]. Based on these findings, a
putative role for statins in RA was suggested.
A preliminary study done in 15 patients with RA who were
receiving methotrexate as a single disease modifying agent
with no satisfactory responses, showed improvement after
eight weeks of treatment with 40 mg simvastatin [119].
Recently, in a randomized placebo controlled trial [120],
atorvastatin 40 mg was shown to significantly improve
disease activity score after 6 months of therapy although
the effects were modest. The use of disease modifying anti-
rheumatic drugs was rather heterogeneous among the
treatment groups in this study, with more patients receiv-
ing methotrexate in the atorvastatin group. Other limita-
tions were a small study group and a direct effect of statins
on hepatic CRP synthesis, which could exaggerate the
impression of disease modification.
Osteoporosis
The biologic effects of statins on bone metabolism have
been reported in literature [121]. Statins were shown to be
potent stimulators of bone formation in vitro. Statins were
shown to stimulate the bone morphogenic protein-2
(BMP-2) promoter in an immortalized osteoblast cell line
[121]. BMP-2 is known to enhance osteoblast differentia-
tion [122]. Further supporting evidence for its beneficial
role came from osteoporosis observational studies [123-
126]. However, in these studies, no adjustment for weight
was made and part of the protective effect of statins could
be because of reduction in weight.
By contrast, the Women's Health Initiative Observation
Study found no relationship between statins and hip/
wrist/arm/non-spine fracture rates after adjusting for
weight and other potential confounders [127]. Lack of
benefit of statins in reducing hip and non-spine fracture
was also reported in a case control study from the General
Practice Research Database [128]. In the first placebo-con-
trolled trial specifically designed to assess bone turnover,
statin treatment did not show any difference in rates of
bone formation [129]. Other uncontrolled studies have
been conflicting; both increased [130] and decreased
[131,132] rates of bone formation have been reported. In
spate of high optimism, it has been suggested that increas-
ing the bioavailability of statins to the bone may lead to
better results [133]. As of now, keeping in mind lack of a
consistent response with statins in various studies, it willJournal of Negative Results in BioMedicine 2005, 4:3 http://www.jnrbm.com/content/4/1/3
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be inappropriate to conclude that statins have a meaning-
ful benefit for patients with osteoporosis.
Cancer
Similar to most of the above mentioned indications, the
action of statins in cancer has been bi-fold with arguments
and evidence both in favour and against having been
published.
It was suggested, nearly a decade ago, that cholesterol
inhibition could inhibit tumour cell growth and possibly
prevent carcinogenesis [134]. Recently, statin use was
shown to be associated with a reduced risk of breast [135]
and colorectal [136] carcinoma. However, these findings
need confirmation as they were based on a small number
of events. Statin use has been associated with a 20%
reduction in colon cancer, if used for more than 4 years
and if more than 1350 defined daily doses were taken
[136].
Evidence to the contrary has also grown simultaneously.
Epidemiological studies in the early 1990s had shown a
rise in non-cardiovascular mortality, particularly cancer
deaths in people with low cholesterol concentrations
[137]. Similar conclusions have been drawn from results
of early trials of cholesterol lowering [138]. Some
researchers have shown that lipid-lowering drugs, includ-
ing statins, increase the occurrence of several types of can-
cer in rodents [139]. In the CARE trial [6], incidence of
female breast cancer and in the PROSPER trial [8] in eld-
erly, incidence of all cancers increased in patients given
pravastatin.
With such conflicting evidence available there is a need
for exercising cautious scepticism for a potential beneficial
role of statins for cancers.
Acquired Immune Deficiency Syndrome
Hyperlipidemia induced by antiretroviral treatment is
observed frequently and can cause an increase in cardio-
vascular risk in HIV patients [139]. Moreover, HIV infec-
tion itself induces pro-atherogenic lipid changes, which
may lead to an increased cardiovascular risk but are partly
reversed by antiretroviral regimens [140]. Statins, given to
patients with HIV infection and hyperlipidemia, effec-
tively reduced total cholesterol (27%) and triglycerides
(15%) [141]. In the first double-blind, placebo-controlled
study of the effects of statin therapy on lipids, lipoprotein
subfractions, and endothelial function in HIV patients
taking protease inhibitors, pravastatin reduced concentra-
tions of atherogenic lipoproteins [142]. Similar beneficial
effects of statins were shown in a cohort of 245 patients
[143]. However, in all these studies the decrease in total
cholesterol, LDL and triglycerides was only modest, and a
significant number of patients did not achieve their NCEP
goals. Moreover, the risk of rhabdomyolysis with concom-
itant use of statins in patients receiving highly active anti-
retroviral therapy needs to be carefully evaluated in future
studies.
Statins have been shown to have a direct effect on HIV
infection itself [144,145]. In in vitro studies, 9 days after
viral loading, lovastatin inhibited both sterol synthesis
and viral multiplication in Human H9 lymphocytic cell
line [144]. Rho-guanosine triphosphatase (GTPase) activ-
ity is required for HIV infectivity into the cells [145]. Stat-
ins block Rho-A activation induced by HIV-1 binding to
target cells and also inhibited entry of HIV-1 pseudotyped
viruses. These data are only experimental and considera-
ble work will need to be done before any speculations for
anti-retroviral potentials of statins are made.
Other indications
Some of the other uses for which statins are being evalu-
ated are drug-induced dyslipidemia following transplan-
tation [146,147], for causing immunosuppression in
patients undergoing organ transplantation [148], promo-
tion of fracture healing in vascularised bone allograft
[149], sickle cell anemia [150,151], idiopathic pulmonary
fibrosis [152,153], sensorimotor recovery after experi-
mental intra-cerebral haemorrhage [154], sepsis [155-
157], and glomerulonephritis [158]. However, only lim-
ited, preliminary data are available to support routine use
of statins in most of these indications and no recommen-
dations can be made at present.
Safety issues
One cannot ignore the safety concerns with statin use;
besides the well known side effects of myopathy, procar-
cinogenesis potential [159,160], nerve damage [161,162],
short temper [163], cognitive decline [164], memory loss
[165], teratogenic potential [166,167], and more recently
loss of libido [168] are some of the other concerns.
The rise, plateau and fall (?) of statins
There is no doubt that statins have become one of the
most commonly utilized drugs in cardiac patients not
only in developed [169] but also in developing nations
[170]. It is also obvious that their use will be intensively
promoted in many non-cardiac conditions discussed
above although the tremendous promise seen in some
experimental and initial clinical studies failed to be sus-
tained in clinical trials or if it did the effect was only mod-
est. For others the initial conflicting results continue to
exist.
Recent years have shown a kind of contagiousness being
demonstrated in research. Foremost among these have
been the case of COX-2 inhibitors. After the discovery of
COX-2 isoenzyme, almost every pathophysiologicalJournal of Negative Results in BioMedicine 2005, 4:3 http://www.jnrbm.com/content/4/1/3
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process showed involvement of COX-2 [171,172]. Selec-
tive inhibition of COX-2 was thought to be the answer to
a number of problems in therapeutics. A large number of
studies giving evidence to the contrary or addressing
adverse effects of COX-2 inhibitors got overshadowed (or
were suppressed) in the hype created over COX-2 inhibi-
tors [173,174]. Rofecoxib and some other selective COX-
2 inhibitors are being withdrawn for their adverse effect
profiles as their discoverer companies gear up for pay-
ments of compensation claims made by sufferers. Many
other molecules have suffered similar fate and we hypoth-
esized that statin research may also be on decline.
To test this hypothesis we searched Medline using the
MeSH term "statins", "statins AND cancer (as well as other
indications one by one)" for overall and yearwise extrac-
tion of citations. A total of approximately 11,000 citations
were found out of which about 50% have appeared in
only the past 4 years (since our last review [2]). An analy-
sis of yearly trends showed some interesting details. The
first study on statins was reported in 1975 [175]. Subse-
quently, there was a steady increase in the publications
until pleiotropism of statins was suggested in the mid-90s
[176] and since then (especially since 2000), a steep rise
in publications for various indications with a peak around
2002–2003 can be noticed. It is interesting to note that a
trend towards a decline in the number of these studies can
already be seen for statins in general (Fig 1) and in many
indications specifically (Fig 2). This declining trend is
probably due to failure to establish any definite benefit in
majority of the indications for which their use was
proposed.
Therefore, our hypothesis which appeared quite implausi-
ble initially may not have been altogether wide of the
mark. Consequently, it remains to be seen whether statins
can withstand the test of time or will sink into oblivion
like many of the other molecules.
Number of statin publications in each year from 1974 to 2004 Figure 1
Number of statin publications in each year from 1974 to 2004. The numbers depict the citations obtained from Pubmed on 
entering the MeSH term 'Statins'Journal of Negative Results in BioMedicine 2005, 4:3 http://www.jnrbm.com/content/4/1/3
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Conclusion
If we take an overview of the evidence available for each
of the above indications of statins we notice that it is
rather weak even for the indications in which there are
controlled trials available. Moreover, these trials are either
inadequately powered or have measured only soft end-
points or have been of short duration to be conclusive.
And lastly, a considerable number of contradictory studies
make their utility in most of these diverse conditions
doubtful.
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